multiple myeloma
The Seattle-based company recently completed a strategic reorganization around its two major business areas by cutting the workforce and appointing a new CFO.
Genetron Health Nabs CE Mark for Blood Cancer Residual Disease Test Kit
The assay uses the company's "One-step Seq" method to detect cancer-associated DNA sequences in bone marrow from patients with certain hematologic cancers.
Adaptive Biotechnologies to Focus on Immune Medicine, Minimal Residual Disease Testing Businesses
Premium
The Seattle-based company said this week that its immune medicine and minimal residual disease testing business arms will drive the firm's future growth.
Sebia, Metafora Biosystems Partner to Develop IVD Tests
Metafora's single-cell diagnostic platform uses artificial intelligence to detect cellular metabolism anomalies.
Natera Q1 Revenues Grow 62 Percent
The company reported $152.3 million in total revenues for the quarter and said the number of tests it processed rose 48 percent from the prior-year quarter.
Feb 26, 2020
Adaptive Biotechnologies Q4 Revenues Rise 41 Percent
Aug 14, 2019
Feb 15, 2018
Dec 13, 2017
Abingdon Health Raises £1.1M
Apr 18, 2017
Oct 21, 2016